Challenges in the development of drugs for the treatment of tuberculosis

Tuberculosis infection is a serious human health threat and the early 21st century has seen a remarkable increase in global tuberculosis activity. The pathogen responsible for tuberculosis is Mycobacterium tuberculosis, which adopts diverse strategies in order to survive in a variety of host lesions. These survival mechanisms make the pathogen resistant to currently available drugs, a major contributing factor in the failure to control the spread of tuberculosis. Multiple drugs are available for clinical use and several potential compounds are being screened, synthesized, or evaluated in preclinical or clinical studies. Lasting and effective achievements in the development of anti-tuberculosis drugs will depend largely on the proper understanding of the complex interactions between the pathogen and its human host. Ample evidence exists to explain the characteristics of tuberculosis. In this study, we highlighted the challenges for the development of novel drugs with potent bacteriostatic or bactericidal activity, which reduce the minimum time required to cure tuberculosis infection.

• Publication year

  2013

• Venue

  Brazilian Journal of Infectious Diseases

• Publication date

  2013-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.bjid.2012.10.009PMID 23287547PMCID 9427384
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Drug Resistance in Mycobacterium tuberculosis

  2017cited by this paper
• New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future.

  2012cited by this paper
• Tuberculosis, drug resistance, and the history of modern medicine.

  2012cited by this paper
• The global plan to stop TB 2011-2015 : transforming the fight towards elimination of tuberculosis

  2011cited by this paper
• Exploiting bacterial DNA gyrase as a drug target: current state and perspectives

  2011cited by this paper
• The Population Dynamics and Control of Tuberculosis

  2010cited by this paper
• Global tuberculosis drug development pipeline: the need and the reality.

  2010cited by this paper
• Early Bactericidal Activity and Pharmacokinetics of PA-824 in Smear-Positive Tuberculosis Patients

  2010cited by this paper
• Drugs in Development for Tuberculosis

  2010cited by this paper
• Biomarker-Assisted Dose Selection for Safety and Efficacy in Early Development of PNU-100480 for Tuberculosis

  2010cited by this paper
• A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy

  2010cited by this paper
• A consistent log-linear relationship between tuberculosis incidence and body mass index.

  2010cited by this paper
• Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis.

  2009cited by this paper
• Clinical experience with the combined use of lopinavir/ritonavir and rifampicin.

  2009cited by this paper
• Mechanisms of drug resistance in Mycobacterium tuberculosis.

  2009cited by this paper
• Tuberculosis and diabetes mellitus: convergence of two epidemics.

  2009cited by this paper
• Assessment of global capacity to conduct tuberculosis drug development trials: do we have what it takes?

  2009cited by this paper
• Drivers of tuberculosis epidemics: the role of risk factors and social determinants.

  2009influential reference
• Pharmacokinetic interactions between rifabutin and lopinavir/ritonavir in HIV-infected patients with mycobacterial co-infection.

  2009cited by this paper
• Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis

  2009cited by this paper
• Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance.

  2009cited by this paper
• A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis

  2009cited by this paper
• Antibiotics for Emerging Pathogens

  2009cited by this paper
• Effect of pyrazinamidase activity on pyrazinamide resistance in Mycobacterium tuberculosis.

  2009cited by this paper
• New Drugs against Tuberculosis: Problems, Progress, and Evaluation of Agents in Clinical Development

  2008cited by this paper
• Selectivity of TMC207 towards Mycobacterial ATP Synthase Compared with That towards the Eukaryotic Homologue

  2008cited by this paper
• Powerful Bactericidal and Sterilizing Activity of a Regimen Containing PA-824, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis

  2008cited by this paper
• A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.

  2008cited by this paper
• Diarylquinolines Are Bactericidal for Dormant Mycobacteria as a Result of Disturbed ATP Homeostasis*

  2008cited by this paper
• Promising Antituberculosis Activity of the Oxazolidinone PNU-100480 Relative to That of Linezolid in a Murine Model

  2008cited by this paper
• Linezolid in the treatment of 'difficult' multidrug-resistant tuberculosis.

  2008cited by this paper
• In Vitro Antimycobacterial Spectrum of a Diarylquinoline ATP Synthase Inhibitor

  2007cited by this paper
• Drugs for bad bugs: confronting the challenges of antibacterial discovery

  2007cited by this paper
• Diarylquinolines target subunit c of mycobacterial ATP synthase.

  2007cited by this paper
• Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis.

  2007cited by this paper
• Diabetes and the risk of tuberculosis: a neglected threat to public health?

  2007cited by this paper
• Effects of Rifampin and Multidrug Resistance Gene Polymorphism on Concentrations of Moxifloxacin

  2007cited by this paper
• Combinations of R207910 with Drugs Used To Treat Multidrug-Resistant Tuberculosis Have the Potential To Shorten Treatment Duration

  2006cited by this paper
• Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.

  2006cited by this paper
• Combination Chemotherapy with the Nitroimidazopyran PA-824 and First-Line Drugs in a Murine Model of Tuberculosis

  2006cited by this paper
• Drug resistance in Mycobacterium tuberculosis.

  2006cited by this paper
• Multidrug-resistant tuberculosis.

  2006cited by this paper
• Synergistic Activity of R207910 Combined with Pyrazinamide against Murine Tuberculosis

  2006cited by this paper
• Outpatient gatifloxacin therapy and dysglycemia in older adults.

  2006cited by this paper
• Preclinical Testing of the Nitroimidazopyran PA-824 for Activity against Mycobacterium tuberculosis in a Series of In Vitro and In Vivo Models

  2005cited by this paper
• A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis

  2005cited by this paper
• A Convergent Enantioselective Route to Structurally Diverse 6-Deoxytetracycline Antibiotics

  2005cited by this paper
• Bactericidal Activity of the Nitroimidazopyran PA-824 in a Murine Model of Tuberculosis

  2005cited by this paper
• Correction

  2004cited by this paper
• Moxifloxacin and Glucose Homeostasis

  2004cited by this paper
• Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid.

  2003cited by this paper
• Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru.

  2003cited by this paper
• Molecular analysis of rifampicin-resistant Mycobacterium tuberculosis isolated in Spain (1996-2001). Description of new mutations in the rpoB gene and review of the literature.

  2003cited by this paper
• Pharmacokinetic Interactions with Rifampicin

  2003cited by this paper
• Gatifloxacin and Ethionamide as the Foundation for Therapy of Tuberculosis

  2003cited by this paper
• In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis.

  2002cited by this paper
• Mutations in the embB locus among Korean clinical isolates of Mycobacterium tuberculosis resistant to ethambutol.

  2002cited by this paper
• The genetics and biochemistry of isoniazid resistance in mycobacterium tuberculosis.

  2000cited by this paper
• Molecular Genetic Analysis of Nucleotide Polymorphisms Associated with Ethambutol Resistance in Human Isolates ofMycobacterium tuberculosis

  2000cited by this paper
• Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis.

  1999cited by this paper
• The molecular basis of isoniazid resistance in Mycobacterium tuberculosis.

  1999cited by this paper
• Role of Acid pH and Deficient Efflux of Pyrazinoic Acid in Unique Susceptibility of Mycobacterium tuberculosis to Pyrazinamide

  1999cited by this paper
• Multidrug resistant tuberculosis.

  1998cited by this paper
• A Ser315Thr Substitution in KatG Is Predominant in Genetically Heterogeneous Multidrug-Resistant Mycobacterium tuberculosis Isolates Originating from the St. Petersburg Area in Russia

  1998cited by this paper
• Mycolic acids: structure, biosynthesis and physiological functions.

  1998cited by this paper
• Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update.

  1998cited by this paper
• The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol

  1997cited by this paper
• Site‐directed mutagenesis of the katG gene of Mycobacterium tuberculosis: effects on catalase–peroxidase activities and isoniazid resistance

  1996cited by this paper
• Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus

  1996cited by this paper
• inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis.

  1994cited by this paper
• Mechanisms of drug resistance in Mycobacterium tuberculosis.

  1994cited by this paper
• Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis.

  1993cited by this paper
• The catalase—peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis

  1992cited by this paper
• Multidrug-resistant Tuberculosis

  1992cited by this paper
• Quinolone antimicrobial agents.

  1992cited by this paper
• Pyrazinamide and pyrazinoic acid activity against tubercle bacilli in cultured human macrophages and in the BACTEC system.

  1990cited by this paper
• Inhibition of synthesis of arabinogalactan by ethambutol in Mycobacterium smegmatis

  1989cited by this paper

• Surface-modified dendrimer nanoconjugate for targeting delivery of rifampicin

  2025cites this paper
• Natural Products with Potent Antimycobacterial Activity (2000–2024): A Review

  2025cites this paper
• Development of Mycobacterium tuberculosis Enoyl Acyl Reductase (InhA) Inhibitors: A Mini-Review.

  2024cites this paper
• Special Issue “Antimicrobial Biomaterials: Recent Progress”

  2024cites this paper
• Recent research progress in the plant contribution to the management of tuberculosis

  2024cites this paper
• Novel Benzylamine Derivatives: Synthesis, Anti-Mycobacterium Tuberculosis Evaluation and Predicted ADMET Properties

  2023cites this paper
• The crystal structure of the salt: 4-((1,3-dioxoisoindolin-2-yl)carbamoyl)pyridine-1-ium 2-carboxybenzoate, C14H10N3O3·C8H5O4

  2023cites this paper
• A novel class of antimicrobial drugs selectively targets a Mycobacterium tuberculosis PE-PGRS protein

  2022influential citation
• Hepatic Adverse Effects of Anti-Mycobacterium Tuberculosis Drugs and Their Associations with Various Genetic Variants

  2022cites this paper
• High proportion of RR-TB and mutations conferring RR outside of the RRDR of the rpoB gene detected in GeneXpert MTB/RIF assay positive pulmonary tuberculosis cases, in Addis Ababa, Ethiopia

  2022cites this paper
• Increased Susceptibility of Mycobacterium tuberculosis to Ethionamide by Expressing PPs-Induced Rv0560c

  2022cites this paper
• Nanoparticle-Based Inhalation Therapy for Pulmonary Diseases.

  2022cites this paper
• Insights into innovative therapeutics for drug-resistant tuberculosis: Host-directed therapy and autophagy inducing modified nanoparticles

  2022cites this paper
• Drug Resistance in Mycobacterium tuberculosis and its Impact on Modern Medicine

  2022cites this paper
• Synthesis of new 2-(thiazol-4-yl)thiazolidin-4-one derivatives as potential anti-mycobacterial agents.

  2021cites this paper
• Modern Drug Discovery and Development for TB: The India Narrative

  2021cites this paper
• Synthesis and biological evaluation of copper and cobalt complexes of (5-substituted-salicylidene) isonicotinichydrazide derivatives as antitubercular agents

  2020cites this paper
• Serum proteins TGFBI, PCSK9, and CCL14 are potential biomarkers for different traditional Chinese medicine syndromes of multidrug‐resistant tuberculosis

  2020cites this paper
• LipF increases rifampicin and streptomycin sensitivity in a Mycobacterium tuberculosis surrogate

  2020cites this paper
• Plant-based Food Products for Antimycobacterial Therapy

  2020cites this paper
• Combination antituberculosis therapy: Opportunities and challenges to combat drug-resistant tuberculosis

  2020cites this paper
• Chemical composition, cytotoxicity and anti-mycobacterium activities of Clausena anisata essential oils

  2020cites this paper
• Dendrimer-based drug delivery systems for tuberculosis treatment

  2020cites this paper
• Application of three dimensional (3D) tumor cell culture systems and mechanism of drug resistance.

  2019cites this paper
• Enhancement of immune response against Mycobacterium tuberculosis HspX antigen by incorporation of combined molecular adjuvant (CASAC).

  2019cites this paper
• Dysregulation of VEGF-dependent angiogenesis in cavernous lung tuberculosis.

  2019cites this paper
• Drug targets exploited in Mycobacterium tuberculosis: Pitfalls and promises on the horizon.

  2018cites this paper
• Phenolic acid-tethered isoniazid for abrogation of drug-induced hepatotoxicity: design, synthesis, kinetics and pharmacological evaluation

  2018cites this paper
• Ethambutol targets the glutamate racemase of Mycobacterium tuberculosis—an enzyme involved in peptidoglycan biosynthesis

  2018cites this paper
• Effects of Mycobacterium Tuberculosis Macrophage Interaction: Surface Energetic Mechanism

  2018influential citation
• Protective immune mechanisms of Yifei Tongluo, a Chinese herb formulation, in the treatment of mycobacterial infection

  2018cites this paper
• Synthesis of carbohydrazides and carboxamides as anti-tubercular agents.

  2018cites this paper
• Mycobacterial Dormancy Systems and Host Responses in Tuberculosis

  2017cites this paper
• Cell wall: A versatile fountain of drug targets in Mycobacterium tuberculosis.

  2017cites this paper
• Bolstering Immunity through Pattern Recognition Receptors: A Unique Approach to Control Tuberculosis

  2017cites this paper
• Deciphering the regulatory network of microRNAs in tuberculosis infected macrophages : a thesis presented in partial fulfilment of the requirements for the degree of Master of Science in Genetics at Massey University, Albany, New Zealand

  2017influential citation
• Anti-mycobacterium tuberculosis activity of polyherbal medicines used for the treatment of tuberculosis in Eastern Cape, South Africa

  2017cites this paper
• Surface Energetics of Mycobacterium Tuberculosis – Macrophage Interactions

  2016cites this paper
• Anti-tubercular Clofazimine Analogs with Improved Physicochemical Properties

  2016cites this paper
• Opportunities and Challenges for Natural Products as Novel Antituberculosis Agents

  2016cites this paper
• Surface Thermodynamics Approach to Mycobacterium tuberculosis (M-TB) – Human Sputum Interactions

  2015cites this paper
• Recent Advances in the Development of Anti-tuberculosis Drugs Acting on Multidrug-Resistant Strains: A review

  2015cites this paper
• Chinese herbal medicine as adjuvant treatment to chemotherapy for multidrug-resistant tuberculosis (MDR-TB): A systematic review of randomised clinical trials.

  2015cites this paper
• Theoretical and experimental study of inclusion complexes formed by isoniazid and modified β-cyclodextrins: 1H NMR structural determination and antibacterial activity evaluation.

  2014influential citation
• Development of a Highly Biocompatible Antituberculosis Nanodelivery Formulation Based on Para-Aminosalicylic Acid—Zinc Layered Hydroxide Nanocomposites

  2014cites this paper